Johnson & Johnson (JNJ): Talc update 'encouraging' but outcome remains uncertain - BofA
Tweet Send to a Friend
BofA Securities analyst Geoff Meacham reiterated a Neutral rating and $185.00 price target on Johnson & Johnson (NYSE: JNJ)."The news ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
